new methadose sales and co. info
MethaDose™, the dispensing product deployed in more than 60 sites in Australia and attracting growing international interest, continues to be deployed in Australia. This week Argus has received additional orders for MethaDose™ from a hospital in Victoria which will use the product as part of their provision of services to Corrections Victoria. The deal is worth more than $80,000.
The use of biometrics to provide positive assurance of identification continues to grow in acceptance in the market place, particularly where customers are able to readily identify business improvements and benefits. MethaDose™ clearly prevents the likelihood of overdosing, misdosing and fraudulent acquisition of restricted and/or dangerous drugs while streamlining the dispensing process. Iris recognition offers a degree of accuracy better than DNA matching and is a non-contact technology. When this is combined with robust dispensing software the customer is delivered a unique application which improves their business flow and processes. For example, a 300 patient Sydney clinic reduced their weekly man-hour overhead from 140 hours to 11 using iris based MethaDose™.
The market is increasingly recognizing the strength of this application which has harnessed the unique benefits of biometric identification technology. Argus sees growth in sales of this product, both in Australia and internationally which reflects a growing trend in the community to accept the role biometrics can play in solving critical identification problems.
ASV Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
